REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered Consisting Of One Nitrogen And Five Carbon Atoms > Polycyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos > Pentacyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos > Ring Nitrogen In The Pentacyclo Ring System Is Shared By Five-membered Cyclo And Six-membered Cyclo (e.g., Vincamine, Etc.) Ring Nitrogen In The Pentacyclo Ring System Is Shared By Five-membered Cyclo And Six-membered Cyclo (e.g., Vincamine, Etc.)Ring Nitrogen In The Pentacyclo Ring System Is Shared By Five-membered Cyclo And Six-membered Cyclo (e.g., Vincamine, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027175 - Antineoplastic activities of ellipticine and its derivatives The present invention describes selective cell growth inhibition of myeloma cells by ellipticine derivatives, 9-methoxy ellipticine and 9-dimethyl amino-ethoxy ellipticine. The cell growth inhibition efficacy was highest for 9-dimethyl amino-ethoxy ellipticine among the ellipcitine derivatives tested. The cell toxicity of 9-dimethyl amino-ethoxy ellipticine was selective for myeloma cells and did ... 12/28/06 - 20060293357 - Intermediates for synthesis of vinblastine, process for preparation of the intermediates and process for synthesis of vinblastines A method for synthesis of the compound of general formula A utilizing radical ring forming reaction of thioanilides and using the compound of general formula B as the starting material, synthesizing thioanilide of general formula C by the reaction with compound 1 and the formation of a 11-membered ring by ... 12/14/06 - 20060281776 - Isotope labeled camptothecin derivatives The present invention provides isotope stable labeled camaptothecin analogs including irinotecan and SN-38, a process for their preparation and their use as internal standard in analytical methods. ... 11/16/06 - 20060258697 - Method of augmenting the antitumor activity of anticancer agents A method for augmenting the antitumor activity of anti-cancer agents is provided. The method comprises administering to an individual an anti-cancer and a selenium compound. A method is also provided for inhibiting the growth of a tumor which-has proven to be refractory to anticancer agents. The methods comprises administration of ... 11/16/06 - 20060258696 - Use of opioid antagonists to attenuate endothelial cell proliferation and migration The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists. ... 11/09/06 - 20060252787 - Phospholipid transfer protein (pltp) and cholesterol metabolism A method for controlling cholesterol metabolism in a host, a screening assay for agents that can control cholesterol metabolism, and the agents that may be identified are practiced and determined in relation to the expression of PLTP in HepG2 cells and a clone from these cells, designated HepG2/PLTPpLuc. Particular agents ... 10/19/06 - 20060235040 - Pharmaceutical compositions containing camptothecins A camptothecin-containing pharmaceutical composition which contains: (a) camptothecin or a derivative thereof, and (b) one or more compounds selected from among ascorbic acid or a salt thereof, sodium hydrogen sulfite, sodium sulfite, potassium pyrosulfite, sodium erythorbate, sodium thioglycolate, sodium pyrosulfite, and α-thioglycerin. The pharmaceutical composition is useful in that, after ... 09/28/06 - 20060217407 - Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor A polymorphic form of 9-nitrocamptothecin is provided, the polymorph being characterizable as having, by differential scanning calorimetry, an endotherm at between 273.9 to 275.9° C., and an exotherm at between 279.3 and 281.3° C. ... 08/03/06 - 20060173030 - Antitumoral analogs of lamellarins New lamellarins are provided of the general formula III wherein X is selected from the group consisting of N, O and S; wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are each independently selected from the group consisting of H, OH, OR′, SH, SR′, SO2R′, NHR′, N(R′)2, ... 07/27/06 - 20060167033 - 7-imino derivatives of camptothecin having antitumor activity Processes for the preparation of the compounds of formula (I) and their use in the preparation of medicaments useful in the treatment of tumors, viral infections and antiplasmodium falciparum are also disclosed. ... 07/13/06 - 20060154947 - Quaternary chelidonine and alkaloid derivatives, process for their preparation and their use in manufacture of medicaments The invention relates to alkaloid reaction products obtainable in a process wherein alkaloids are reacted with an alkylating agent, preferably thiotepa, whereafter unreacted alkylating agent and other water-soluble compounds are removed from the reaction mixture by washing with water or a suitable aqueous solvent, whereafter the reaction mixture is subjected ... 06/22/06 - 20060135546 - Methods for the purification of 20(s)- camptothecin The invention features scalable methods for the purification of (20S)-camptothecin. ... 06/15/06 - 20060128736 - Camptothecin-carboxylate formulations The present invention relates to compositions, particularly colloidal nanoaggregates comprising the carboxylate form of a campothecin drug or a derivative thereof associated with at least one organic cationic molecule, which has a positive net charge. The composition or nanoaggregate may be present as an emulsion, droplet, mincelle, liposome, nanoparticle or ... 04/20/06 - 20060084670 - Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer The present invention relates to therapeutic associations for the treatment of cancer, comprising an effective amount of a camptothecin, or a camptothecin derivative, with an effective amount of an alkylating agent such as a platin derivative, and methods of using such therapeutic associations. ... 03/02/06 - 20060046993 - Crystalline polymorphic form of irinotecan hydrochloride This invention relates to a novel crystalline polymorphic form of irinotecan hydrochloride. A process for preparing this novel polymorphic form, pharmaceutical compositions comprising it as an active ingredient and the use of the same and its pharmaceutical compositions as a therapeutic agent is also within the scope of the present ... 02/16/06 - 20060035917 - Medicament component of berberine for the use of prevention and treatment of psycological dependence on and analgesic tolerance to morphine Disclosed is a pharmaceutical composition for preventing and treating addiction to morphine or preventing and inhibiting the development of tolerance to the analgesic effects of morphine, containing berberine as an effective ingredient, wherein the berberine has an inhibitory effect versus psychological dependence on abused drugs such as morphine and the ... 02/09/06 - 20060030578 - Pharmaceutically active lipid based formulation of irinotecan Delivering therapeutic amounts of irinotecan remains limited due to its highly water insoluble properties. This invention overcomes this limitation by presenting a novel method of preparing liposomal irinotecan by first inactivating irinotecan prior to liposome formation and then subsequently activating the irinotecan by lowering the pH of the lipid composition ... 01/19/06 - 20060014773 - Mental agility lozenge, edible strip, food or drink A mental agility composition is composed of at least one agent which promotes synthesis of ATP and/or creatine phosphate in the body; at least one antioxidant for scavenging free radicals in at least one pathway in the body; at least one agent for normalizing or maintaining membrane function and structure ... 01/19/06 - 20060014772 - Phenanthroindolizidine alkaloids A group of novel phenanthroindolizidine alkaloid compounds as shown and their use in treating cancer. Also disclosed are methods of using phenanthroindolizidine alkoid compounds in suppressing NO and TNF-α production, inhibiting MEKK1 activity and cyclooxygenase II expression, and treating NO-related disorders. ... 12/08/05 - 20050272755 - Method for treating abnormal cell growth The present Invention relates to a method of treating abnormal cell growth in a subject, comprising administering to said subject having abnormal cell growth: (a) a compound selected from the group consisting of a camptothecin, a camptothecin derivative, or a pharmaceutically acceptable salt, solvate or prodrug of said compounds; (b) ... 12/01/05 - 20050267141 - Process to prepare camptothecin derivatives A process is provided for the preparation of camptothecin derivatives, such as irinotecan, in a one-pot operation. ... 11/17/05 - 20050256148 - Esters in position 20 of camptothecins Formula (I) compounds are described: (I) where the groups are as defined in the description here below, the racemic mixtures, their individual enantiomers, their individual diastereoisomers, their mixtures, and their pharmaceutically acceptable sales. Said compounds are topoisomerase I inhibitors. ... 11/03/05 - 20050245559 - Treatment and prevention of prostate cancer The present invention provides novel methods of preventing and treating prostate cancer with tetrandrine, a bisphehol-isoquinoline alkaloid isolated from the Chinese herb Stephania tetrandra. The present invention also provides the use of tetrandrine for the manufacture of a pharmaceutical composition for treating prostate cancer. The tetrandrine can be used as ... 09/08/05 - 20050197355 - Compounds useful in preparing camptothecin derivatives and salts thereof, where R1 is hydrogen, an alkyl, aralkyl, hydroxymethyl, carboxymethyl, acyloxymethyl or trialkylsilyl group, or a group —CH2NR3R4 where N is a linking nitrogen atom and where (a) R3 and R4 are independently selected from hydrogen and alkyl, alkenyl, hydroxyalkyl and alkoxyalkyl groups; (b) R3 is hydrogen or ... 08/25/05 - 20050187240 - Aaptamine and isoaaptamine and structural modifications thereof Disclosed herein is the isolation and elucidation of the structure of isoaptamine (2), and its conversion to numerous novel related compounds, which appear to have antimicrobial and/or cancer fighting properties. Also disclosed is the conversion of isoaaptamine (2) to the phosphate prodrug hystatin 1 (11), as well as the conversion ... 08/11/05 - 20050176748 - Vinorelbine derivatives The present invention relates to novel vinorelbine derivatives. Pharmaceutical compositions containing these compounds as well as processes of preparation and processes of use for treatment of various conditions are also disclosed. ... 08/11/05 - 20050176747 - Use of benzo[c]quinolizinium derivatives for the treatment of diseases that are linked to smooth muscle cell constriction The invention relates to the use of benzo[c]quinolizinium derivatives for treating diseases that are linked to smooth muscle cell constriction, such as hypertension and asthma. ... 07/14/05 - 20050154004 - Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents wherein, A is a cyclic or non-cyclic group; Z is a carbon or a heteroatom; n is selected from 0, 1, 2 or 3; W, X and Y may be the same or different and each are selected from hydrogen; optionally substituted alkyl, alkenyl, alkynyl, amino, alkoxy, alkenoxy, alkynoxy, aryl, ... 07/14/05 - 20050154003 - Camptothecins with a modified lactone ring Compounds of formula (I) or (II) are described: where the groups are as defined in the description here below, the racemic mixtures, their individual enantiomers, their individual diastereoisomers, their mixtures, and their pharmaceutically acceptable salts. Said compounds are topoisomerase I inhibitors. ... ### FreshPatents.com Support |